CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Clinical trials for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) explained in plain language.
Never miss a new study
Get alerted when new CLEAR CELL RENAL CELL CARCINOMA (CCRCC) trials appear
Sign up with your email to follow new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThis study tests a new drug called REGN5678, given alone or with another drug (cemiplimab), in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the combination can safely shrink tumors by helping the immune system attack cancer c…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kidney cancer: triple-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests three different drug combinations in 120 people with advanced kidney cancer that has spread. The goal is to see which combination works best to shrink tumors. Participants will receive either a new two-drug or three-drug combination, or a standard two-drug therap…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE2 • Sponsor: Brian Rini • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug i…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo may help save kidneys in High-Risk cancer patients
Disease control Recruiting nowThis study tests whether giving two drugs (pucotenlimab and vorolanib) before surgery can shrink kidney tumors enough to allow partial kidney removal instead of full removal. It includes 21 adults with high-risk clear cell renal cancer who need surgery but have tumors that make k…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC